{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:58:48Z","timestamp":1782943128042,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This study was sponsored by Alexion, AstraZeneca Rare Disease."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04321-x","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T10:47:54Z","timestamp":1754390874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Demographics and baseline disease characteristics of UK patients within the global aHUS registry"],"prefix":"10.1186","volume":"26","author":[{"given":"Rodney D.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Al-Dakkak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Boothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Sheerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"4321_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.med.59.060106.185110","volume":"59","author":"D Kavanagh","year":"2008","unstructured":"Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med. 2008;59:293\u2013309.","journal-title":"Annu Rev Med"},{"key":"4321_CR2","doi-asserted-by":"crossref","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2017;91(3):539\u201351.","DOI":"10.1016\/j.kint.2016.10.005"},{"issue":"Suppl 11","key":"4321_CR3","first-page":"2","volume":"14","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14(Suppl 11):2\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"key":"4321_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: A systematic literature review. Clin Epidemiol. 2020;12:295\u2013305.","journal-title":"Clin Epidemiol"},{"issue":"6","key":"4321_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508\u201330.","journal-title":"Semin Nephrol"},{"issue":"11","key":"4321_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, et al. Dynamics of complement activation in aHUS and how to monitor Eculizumab therapy. Blood. 2014;124(11):1715\u201326.","journal-title":"Blood"},{"key":"4321_CR7","doi-asserted-by":"crossref","unstructured":"Liu Y, Thaker H, Wang C, Xu Z, Dong M. Diagnosis and treatment for Shiga Toxin-Producing Escherichia coli associated hemolytic uremic syndrome. Toxins (Basel) 2022, 15(1).","DOI":"10.3390\/toxins15010010"},{"key":"4321_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Eculizumab for treating atypical haemolytic uraemic syndrome [https:\/\/www.nice.org.uk\/guidance\/hst1]"},{"key":"4321_CR9","doi-asserted-by":"crossref","unstructured":"Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, Bigirumurame T, Dutt T, Montgomery EK, Malina M et al. Atypical haemolytic uraemic syndrome in the era of terminal complement inhibition- an observational cohort study. Blood 2023.","DOI":"10.1182\/blood.2022018833"},{"issue":"10","key":"4321_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, et al. Relative role of genetic complement abnormalities in sporadic and Familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4321_CR11","doi-asserted-by":"crossref","unstructured":"Bogdan RG, Anderco P, Ichim C, Cimpean AM, Todor SB, Glaja-Iliescu M, Crainiceanu ZP, Popa ML. Atypical hemolytic uremic syndrome: A review of complement dysregulation, genetic susceptibility and multiorgan involvement. J Clin Med 2025, 14(7).","DOI":"10.3390\/jcm14072527"},{"issue":"21","key":"4321_CR12","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","volume":"129","author":"TS Jokiranta","year":"2017","unstructured":"Jokiranta TS. HUS and atypical HUS. Blood. 2017;129(21):2847\u201356.","journal-title":"Blood"},{"issue":"6","key":"4321_CR13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Provot F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grange S, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95(6):1443\u201352.","journal-title":"Kidney Int"},{"issue":"4","key":"4321_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4321_CR15","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Barratt J, Beck LH Jr., Fakhouri F, Gale DP, de Jorge G E, Mosca M, Noris M, P MC, S K, et al. The role of complement in kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2024;106(3):369\u201391.","DOI":"10.1016\/j.kint.2024.05.015"},{"issue":"1","key":"4321_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3904\/kjim.2019.388","volume":"35","author":"H Lee","year":"2020","unstructured":"Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25\u201340.","journal-title":"Korean J Intern Med"},{"issue":"2","key":"4321_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408\u201318.","journal-title":"Kidney Int"},{"issue":"3","key":"4321_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40620-022-01465-z","volume":"36","author":"JM Halimi","year":"2023","unstructured":"Halimi JM, Al-Dakkak I, Anokhina K, Ardissino G, Licht C, Lim WH, Massart A, Schaefer F, Walle JV, Rondeau E. Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the global aHUS registry. J Nephrol. 2023;36(3):817\u201328.","journal-title":"J Nephrol"},{"issue":"8","key":"4321_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/nep.14304","volume":"29","author":"C Licht","year":"2024","unstructured":"Licht C, Al-Dakkak I, Anokhina K, Isbel N, Fremeaux-Bacchi V, Gilbert RD, Greenbaum LA, Ariceta G, Ardissino G, Schaefer F, et al. Characterization of patients with aHUS and associated triggers or clinical conditions: A global aHUS registry analysis. Nephrol (Carlton). 2024;29(8):519\u201327.","journal-title":"Nephrol (Carlton)"},{"issue":"8","key":"4321_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00467-018-3933-3","volume":"33","author":"K Fidan","year":"2018","unstructured":"Fidan K, Goknar N, Gulhan B, Melek E, Yildirim ZY, Baskin E, Hayran M, Gulleroglu K, Ozcakar ZB, Ozaltin F, et al. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2018;33(8):1395\u2013403.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"4321_CR21","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00467-018-4039-7","volume":"34","author":"C Formeck","year":"2019","unstructured":"Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019;34(8):1337\u201348.","journal-title":"Pediatr Nephrol"},{"key":"4321_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","volume":"6","author":"C Loirat","year":"2011","unstructured":"Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.","journal-title":"Orphanet J Rare Dis"},{"key":"4321_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","volume":"16","author":"C Licht","year":"2015","unstructured":"Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 2015;16:207.","journal-title":"BMC Nephrol"},{"issue":"9","key":"4321_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/nep.13722","volume":"25","author":"J Soraru","year":"2020","unstructured":"Soraru J, Isbel N, Wong G, Coates PT, Mantha M, Abraham A, Juneja R, Hsu D, Brown F, Bose B, et al. Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): the Australian cohort in a global aHUS registry. Nephrol (Carlton). 2020;25(9):683\u201390.","journal-title":"Nephrol (Carlton)"},{"key":"4321_CR25","doi-asserted-by":"publisher","first-page":"205435811989722","DOI":"10.1177\/2054358119897229","volume":"7","author":"AL Lapeyraque","year":"2020","unstructured":"Lapeyraque AL, Bitzan M, Al-Dakkak I, Francis M, Huang SS, Kaprielian R, Larratt L, Pavenski K, Ribic C, Tosikyan A, et al. Clinical characteristics and outcome of Canadian patients diagnosed with atypical hemolytic uremic syndrome. Can J Kidney Health Dis. 2020;7:2054358119897229.","journal-title":"Can J Kidney Health Dis"},{"issue":"6","key":"4321_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s11560-019-0357-4","volume":"14","author":"CS Haas","year":"2019","unstructured":"Haas CS, Nitschke M, Menne J, Guthoff M, G\u00e4ckler A, Bruck H, Pape L, Vester U, W\u00fchl E, Billing H, et al. Charakterisierung von patienten Mit atypischem h\u00e4molytisch-ur\u00e4mischen syndrom (aHUS) in Deutschland. Der Nephrologe. 2019;14(6):496\u2013504.","journal-title":"Der Nephrologe"},{"key":"4321_CR27","unstructured":"Cresseri D. Sindrome emolitico uremica atipica (SEUa): dati sui pazienti italiani arruolati nel Global aHUS Registry, il registro internazionale per pazienti affetti da sindrome emolitico uremica atipica-L-. In: 57th Congresso Nazionale della Societ\u00e0 Italiana di Nefrologia: 2016; Milan, Italy; 2016."},{"issue":"5","key":"4321_CR28","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40620-021-01025-x","volume":"34","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a global aHUS registry analysis. J Nephrol. 2021;34(5):1581\u201390.","journal-title":"J Nephrol"},{"issue":"8","key":"4321_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ekir.2020.05.003","volume":"5","author":"LA Greenbaum","year":"2020","unstructured":"Greenbaum LA, Licht C, Nikolaou V, Al-Dakkak I, Green J, Haas CS, Roman-Ortiz E, Cheong HI, Sartz L, Swinford R, et al. Functional assessment of fatigue and other Patient-Reported outcomes in patients enrolled in the global aHUS registry. Kidney Int Rep. 2020;5(8):1161\u201371.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4321_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13023-016-0537-5","volume":"11","author":"L Woodward","year":"2016","unstructured":"Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, a Ariceta G. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the global aHUS registry. Orphanet J Rare Dis. 2016;11(1):154.","journal-title":"Orphanet J Rare Dis"},{"key":"4321_CR31","unstructured":"Wong E, Maville C, Allen G, Turnbull C, Forster N, Nicholl H, Winn S, Malina M, Johnson S, Sheerin N et al. The Annual Report of the National Renal Complement Therapeutics Centre 2020\/21. In: The Annual Report of the National Renal Complement Therapeutics Centre. 2021."},{"issue":"4","key":"4321_CR32","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267\u201379.","journal-title":"Blood"},{"issue":"3","key":"4321_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","volume":"106","author":"CM Nester","year":"2024","unstructured":"Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, et al. An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National kidney foundation working group. Kidney Int. 2024;106(3):326\u201336.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04321-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:47:49Z","timestamp":1757357269000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04321-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4321"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04321-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The aHUS Registry is approved through the Research Ethics Committee (REC) North East; Newcastle and North Tyneside 2, chaired by Professor Barry Hirst. The REC approvals are provided to the individual participating sites in the Registry. The Registry is conducted in accordance with International Conference on Harmonisation Good Clinical Practice Guidelines and the Declaration of Helsinki. Written informed consent was provided by patients or their parents or guardians, as deemed applicable by institutional review boards or the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RDG has received several honoraria from Alexion for lectures on aHUS and serving on advisory boards. SDM and AW have no disclosures relating to this manuscript. MSc has received honoraria and a research grant from Alexion. DPG, SG, MSh and NSS have received honoraria from Alexion. CB and TEC are current employees of Alexion, AstraZeneca Rare Disease. IAD, at the time of writing and reviewing, was an employee of AstraZeneca Rare Disease.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"434"}}